The UK Court of Appeal Overturns CAT and Imposes Agency Discretion on Excessive Price Benchmark

Publication Date27 March 2020
SubjectCompetition,Appeals,Fines,Reversal,Abuse of Dominance,Pfizer,UK,Antitrust Violations,UK Competition and Markets Authority (CMA),Excessive Pricing,Pharmaceutical Industry,UK Competition Appeal Tribunal (CAT)
AuthorIngrid Vandenborre,Frederic Depoortere,Giorgio Motta,Bill Batchelor
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT